Is ELTX or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -2,748.16% -151.12% Oncobiologics N/A N/A -291.28%

Which has better earnings & valuation, AVXL or ELTX?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anavex Life Sciences N/A N/A -$46.38M -$0.46 N/A Elicio Therapeutics N/A N/A -$39.57M -$2.40 N/A

Is AVXL or ELTX more profitable?

Anavex Life Sciences' return on equity of -38.76% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -38.76% -35.01% Elicio Therapeutics N/A -2,748.16% -151.12%

Is CGEN or ELTX more profitable?

Compugen has a net margin of 47.97% compared to Elicio Therapeutics' net margin of 0.00%. Compugen's return on equity of 47.72% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Compugen 47.97% 47.72% 27.51% Elicio Therapeutics N/A -2,748.16% -151.12%

Elicio Therapeutics (ELTX) Competitors

$3.00 -0.15 (-4.76%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.08 +0.09 (+2.83%)

As of 07/24/2026 07:34 PM Eastern

Compare

ELTX vs. OTLK, AVXL, DTIL, CGEN, and CHRS

Should you buy Elicio Therapeutics stock or one of its competitors? MarketBeat compares Elicio Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Elicio Therapeutics include Oncobiologics (OTLK), Anavex Life Sciences (AVXL), Precision BioSciences (DTIL), Compugen (CGEN), and Coherus Oncology (CHRS). These companies are all part of the "med - biomed/gene" industry.

How does Elicio Therapeutics compare to Oncobiologics?

Elicio Therapeutics (NASDAQ:ELTX) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by insiders. Comparatively, 1.8% of Oncobiologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Oncobiologics had 6 more articles in the media than Elicio Therapeutics. MarketBeat recorded 7 mentions for Oncobiologics and 1 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.87 beat Oncobiologics' score of 0.31 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Elicio Therapeutics	Very Positive
Oncobiologics	Neutral

Elicio Therapeutics currently has a consensus price target of $19.75, indicating a potential upside of 558.33%. Oncobiologics has a consensus price target of $6.50, indicating a potential upside of 362.63%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Elicio Therapeutics is more favorable than Oncobiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Elicio Therapeutics has higher earnings, but lower revenue than Oncobiologics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A
Oncobiologics	$333.14K	626.66	-$62.42M	-$1.17	N/A

Oncobiologics' return on equity of 0.00% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Oncobiologics	N/A	N/A	-291.28%

Elicio Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Summary

Elicio Therapeutics beats Oncobiologics on 9 of the 14 factors compared between the two stocks.

How does Elicio Therapeutics compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Anavex Life Sciences currently has a consensus target price of $21.33, suggesting a potential upside of 788.89%. Elicio Therapeutics has a consensus target price of $19.75, suggesting a potential upside of 558.33%. Given Anavex Life Sciences' higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than Elicio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Anavex Life Sciences has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A

Anavex Life Sciences' return on equity of -38.76% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Elicio Therapeutics	N/A	-2,748.16%	-151.12%

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by insiders. Comparatively, 50.9% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Anavex Life Sciences had 1 more articles in the media than Elicio Therapeutics. MarketBeat recorded 2 mentions for Anavex Life Sciences and 1 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.87 beat Anavex Life Sciences' score of 1.08 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anavex Life Sciences	Positive
Elicio Therapeutics	Very Positive

Summary

Elicio Therapeutics beats Anavex Life Sciences on 8 of the 13 factors compared between the two stocks.

How does Elicio Therapeutics compare to Precision BioSciences?

Elicio Therapeutics (NASDAQ:ELTX) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Elicio Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market.

In the previous week, Precision BioSciences had 1 more articles in the media than Elicio Therapeutics. MarketBeat recorded 2 mentions for Precision BioSciences and 1 mentions for Elicio Therapeutics. Precision BioSciences' average media sentiment score of 1.89 beat Elicio Therapeutics' score of 1.87 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Elicio Therapeutics	Very Positive
Precision BioSciences	Very Positive

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by insiders. Comparatively, 2.7% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Elicio Therapeutics presently has a consensus price target of $19.75, suggesting a potential upside of 558.33%. Precision BioSciences has a consensus price target of $32.25, suggesting a potential upside of 342.39%. Given Elicio Therapeutics' higher probable upside, research analysts plainly believe Elicio Therapeutics is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Elicio Therapeutics has higher earnings, but lower revenue than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A
Precision BioSciences	$45.07M	4.17	-$45.72M	-$3.67	N/A

Elicio Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -85.37% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Precision BioSciences	-96.73%	-85.37%	-37.34%

Summary

Elicio Therapeutics and Precision BioSciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Elicio Therapeutics compare to Compugen?

Compugen (NASDAQ:CGEN) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

In the previous week, Compugen had 2 more articles in the media than Elicio Therapeutics. MarketBeat recorded 3 mentions for Compugen and 1 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.87 beat Compugen's score of 0.65 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Compugen	Positive
Elicio Therapeutics	Very Positive

Compugen currently has a consensus target price of $5.00, indicating a potential upside of 119.30%. Elicio Therapeutics has a consensus target price of $19.75, indicating a potential upside of 558.33%. Given Elicio Therapeutics' higher probable upside, analysts plainly believe Elicio Therapeutics is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Compugen has higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.66M	2.97	$35.34M	$0.37	6.16
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A

12.2% of Compugen shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 50.9% of Elicio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Compugen has a beta of 2.76, suggesting that its share price is 176% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Compugen has a net margin of 47.97% compared to Elicio Therapeutics' net margin of 0.00%. Compugen's return on equity of 47.72% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Elicio Therapeutics	N/A	-2,748.16%	-151.12%

Summary

Compugen beats Elicio Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Elicio Therapeutics compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, Coherus Oncology had 3 more articles in the media than Elicio Therapeutics. MarketBeat recorded 4 mentions for Coherus Oncology and 1 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.87 beat Coherus Oncology's score of 0.96 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Coherus Oncology	Positive
Elicio Therapeutics	Very Positive

Coherus Oncology has higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.16	$168.02M	$1.67	0.84
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.40	N/A

Coherus Oncology currently has a consensus target price of $8.67, suggesting a potential upside of 514.66%. Elicio Therapeutics has a consensus target price of $19.75, suggesting a potential upside of 558.33%. Given Elicio Therapeutics' higher possible upside, analysts plainly believe Elicio Therapeutics is more favorable than Coherus Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Coherus Oncology has a net margin of 397.30% compared to Elicio Therapeutics' net margin of 0.00%. Coherus Oncology's return on equity of -198.90% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Elicio Therapeutics	N/A	-2,748.16%	-151.12%

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Coherus Oncology has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Summary

Coherus Oncology beats Elicio Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Elicio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELTX vs. The Competition

Export

Metric	Elicio Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$57.26M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.25	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.08	89.45
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	33.33	7.88	10.28	6.07
Net Income	-$39.57M	$23.86M	$3.60B	$331.99M
7 Day Performance	-3.54%	-3.82%	-1.27%	-0.63%
1 Month Performance	-20.00%	-2.61%	-0.37%	-2.00%
1 Year Performance	-69.42%	32.79%	18.30%	13.62%

Elicio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELTX Elicio Therapeutics	3.0556 of 5 stars	$3.00 -4.8%	$19.75 +558.3%	-69.4%	$57.26M	N/A	N/A	N/A	Positive News
OTLK Oncobiologics	3.781 of 5 stars	$1.46 -6.4%	$6.50 +345.2%	-29.8%	$231.80M	$1.35M	N/A	20	News Coverage Gap Up
AVXL Anavex Life Sciences	2.0813 of 5 stars	$2.34 -6.4%	$21.33 +811.7%	-81.2%	$231.68M	N/A	N/A	40	News Coverage Positive News
DTIL Precision BioSciences	2.7118 of 5 stars	$8.32 -5.6%	$32.25 +287.6%	+45.8%	$227.32M	$34.26M	N/A	200	News Coverage Positive News
CGEN Compugen	2.863 of 5 stars	$2.33 -1.3%	$5.00 +114.6%	+48.1%	$223.15M	$72.76M	6.30	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELTX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elicio Therapeutics (ELTX) Competitors

ELTX vs. OTLK, AVXL, DTIL, CGEN, and CHRS

How does Elicio Therapeutics compare to Oncobiologics?

Summary

How does Elicio Therapeutics compare to Anavex Life Sciences?

Summary

How does Elicio Therapeutics compare to Precision BioSciences?

Summary

How does Elicio Therapeutics compare to Compugen?

Summary

How does Elicio Therapeutics compare to Coherus Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elicio Therapeutics (ELTX) Competitors

ELTX vs. OTLK, AVXL, DTIL, CGEN, and CHRS

How does Elicio Therapeutics compare to Oncobiologics?

Do institutionals and insiders hold more shares of ELTX or OTLK?

Does the media prefer ELTX or OTLK?

Do analysts recommend ELTX or OTLK?

Which has better earnings & valuation, ELTX or OTLK?

Is ELTX or OTLK more profitable?

Which has more volatility & risk, ELTX or OTLK?

Summary

How does Elicio Therapeutics compare to Anavex Life Sciences?

Do analysts recommend AVXL or ELTX?

Which has more volatility and risk, AVXL or ELTX?

Which has better earnings & valuation, AVXL or ELTX?

Is AVXL or ELTX more profitable?

Do institutionals & insiders have more ownership in AVXL or ELTX?

Does the media refer more to AVXL or ELTX?

Summary

How does Elicio Therapeutics compare to Precision BioSciences?

Which has more risk and volatility, ELTX or DTIL?

Does the media favor ELTX or DTIL?

Do institutionals & insiders have more ownership in ELTX or DTIL?

Do analysts prefer ELTX or DTIL?

Which has better earnings and valuation, ELTX or DTIL?

Is ELTX or DTIL more profitable?

Summary

How does Elicio Therapeutics compare to Compugen?

Does the media refer more to CGEN or ELTX?

Do analysts recommend CGEN or ELTX?

Which has stronger earnings & valuation, CGEN or ELTX?

Do institutionals and insiders believe in CGEN or ELTX?

Which has more risk and volatility, CGEN or ELTX?

Is CGEN or ELTX more profitable?

Summary

How does Elicio Therapeutics compare to Coherus Oncology?

Does the media favor CHRS or ELTX?

Which has better earnings and valuation, CHRS or ELTX?

Do analysts recommend CHRS or ELTX?

Is CHRS or ELTX more profitable?

Do insiders & institutionals believe in CHRS or ELTX?

Which has more risk & volatility, CHRS or ELTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools